Generalized Anxiety Disorder Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Alkermes PLC, Pfizer Inc., Mind Medicine Inc., Sage Therapeutics Inc., Bionomics Ltd.

The generalized anxiety disorder market size has grown steadily in recent years. It will grow from $7.51 billion in 2023 to $7.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to mental health awareness, pharmaceutical advances, cognitive-behavioral therapy (cbt), stressful lifestyle changes.

The generalized anxiety disorder market size is expected to see steady growth in the next few years. It will grow to $8.89 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to digital mental health solutions, genetic research, integrated care models, global mental health awareness. Major trends in the forecast period include holistic approaches, cultural competence, early intervention, artificial intelligence (ai) in diagnosis.

Market Overview -
Generalized anxiety disorder (GAD) is a mental health condition characterized by excessive and persistent worry, fear and anxiety about various aspects of life. It involves a broad range of concerns that can often feel uncontrollable and overwhelming. The treatment decisions change based on how significantly GAD is affecting a person's ability to function in daily life.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13039&type=smp

Rising Mental Disorder Cases Drive Expansion Of The Generalized Anxiety Disorder Market
The rising number of mental disorder cases in the healthcare industry is driving the growth of the generalized anxiety disorder market. A mental disorder, also known as a mental illness, refers to a wide range of conditions that affect a person's thoughts, emotions, behaviors and overall mental well-being. Mental health disorders that commonly occur with generalized anxiety disorder include phobias, panic disorder, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) and managing these conditions is crucial for individuals to maintain healthy relationships and improve their quality of life. For instance, in April 2023, Forbes Media LLC, a US-based media company, reported that in 2020, 21% of U.S. adults (52.9 million) reported mental illness. Furthermore, in March 2023, according to the National Alliance on Mental Illness, a US-based non-profit organization, 22.8% (57.8 million people) of U.S. adults experienced mental illness in 2021, which increased from previous years. Therefore, the rising number of mental disorder cases is expected to propel the growth of the generalized anxiety disorder market.

Competitive Landscape -
Major players in the generalized anxiety disorder market are Alkermes PLC, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Bristol-Myers Squibb, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, 3M Company, Boehringer Ingelheim International GmbH, Johnson And Johnson Private Limited, Adobe Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Mylan N.V., Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals PLC, Forest Laboratories Inc., H. Lundbeck A/S, Shionogi and Company, Neurocrine Biosciences Inc., Actavis Pharmaceutical Company, Eli Lilly and Company, Noven Pharmaceuticals Inc., Mind Medicine Inc., Sage Therapeutics Inc., Bionomics Ltd., Recordati Rare Diseases SARL, VistaGen Therapeutics Inc.

Innovative Drug Development Revolutionizes Generalized Anxiety Disorder Treatment
Major companies operating in the generalized anxiety disorder market are developing innovative drugs such as MM-120 and getting approval for the treatment of generalized anxiety disorder to better meet the needs of their existing consumers. Innovative drugs such as MM-120 aim to improve the management and outcomes of this mental health condition. For instance, in January 2022, Mind Medicine Inc., a US-based psychedelic medicine biotech company, received approval for an Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), allowing the company's phase IIb dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed. MM-120 is a small molecule that acts as a partial agonist of the 5-HT2A receptor. This receptor is involved in the regulation of mood, anxiety and perception. Moreover, MM-120 is thought to work by increasing serotonin levels in the brain and this could pave the way for other psychedelic compounds to be developed to treat mental health disorders.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/generalized-anxiety-disorder-global-market-report

Key Segments -
The generalized anxiety disorder market covered in this report is segmented -
1) By Type: Panic Disorder; Agoraphobia; Generalized Anxiety; Social Anxiety; Specific Phobia; Other Types
2) By Therapies: Interpersonal Therapy; Behavior Therapy; Cognitive Behavioral Therapy; Mindfulness Based Cognitive Therapy
3) By Device: Deep Brain Stimulation; Electroconvulsive Therapy; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.